Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood, tissue and other materials; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and also through a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.
Headquarters
Netherlands
Address
Hulsterweg 82, Venlo, 5912PL
Website
www.qiagen.com
Telephone
31 77 3556600
No of Employees
6,000
Industry
Medical Equipment
Ticker Symbol & Exchange
QIA (ETR)
Revenue (2021)
$2.3B
20.4%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
42.7%
(2021 vs 2020)
Market Cap*
$10.0B
Net Profit Margin (2021)
XXX
18.6%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Services |
|---|---|
| Sample Technologies: | Laboratory and Genomic Services |
| Primary Sample Technology Consumables | |
| Secondary Sample Technology Consumables | |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In June, the company partnered with TCS in driving its cloud transformation strategy. |
| 2022 | New Products/Services | In May, the company announced the launch of QIAstat-Dx Rise a high-capacity version of the QIAstat-Dx automated syndromic system. |
| 2022 | Contracts/Agreements | In May, the company signed an agreement to acquire a 96% stake in BLIRT SA, a manufacturer of recombinant enzymes. |
Competitor Comparison
| Key Parameters | Qiagen NV | Roche Diagnostics International Ltd | Hologic Inc | 4basebio AG | Macherey-Nagel GmbH & Co KG |
|---|---|---|---|---|---|
| Headquarters | Netherlands | Switzerland | United States of America | Germany | Germany |
| City | Venlo | Rotkreuz | Marlborough | Heidelberg | Duren |
| State/Province | - | Zug | Massachusetts | - | Nordrhein-Westfalen |
| No. of Employees | 6,000 | 2,600 | 6,705 | 2 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thierry Bernard | Chief Executive Officer; Managing Director | Senior Management | 2020 | 57 |
| Roland Sackers | Managing Director; Chief Financial Officer | Senior Management | 2006 | 53 |
| Lawrence A. Rosen | Chairman | Non Executive Board | 2020 | 64 |
| Stephany Foster | Head - Human Resources; Senior Vice President | Senior Management | 2019 | - |
| Dr. Jonathan Sheldon | Senior Vice President - QIAGEN Digital Insights Business Area | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer